The combination of ivosidenib—an IDH1 inhibitor—and azacitidine has been approved by the FDA for the treatment of older adults with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) [261]. The gene discussed is IDH1; the disease is acute myeloid leukemia.